Brokerages Anticipate Corium International Inc (CORI) Will Post Earnings of -$0.39 Per Share

Equities analysts expect that Corium International Inc (NASDAQ:CORI) will announce earnings per share of ($0.39) for the current quarter, Zacks reports. Two analysts have issued estimates for Corium International’s earnings. The highest EPS estimate is ($0.33) and the lowest is ($0.44). Corium International reported earnings of ($0.43) per share in the same quarter last year, which would indicate a positive year over year growth rate of 9.3%. The firm is expected to announce its next earnings report on Thursday, August 2nd.

On average, analysts expect that Corium International will report full year earnings of ($1.59) per share for the current year, with EPS estimates ranging from ($1.73) to ($1.50). For the next year, analysts forecast that the business will report earnings of ($1.46) per share, with EPS estimates ranging from ($1.74) to ($1.09). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Corium International.

Corium International (NASDAQ:CORI) last posted its quarterly earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.04). Corium International had a negative return on equity of 273.01% and a negative net margin of 156.05%. The firm had revenue of $10.06 million for the quarter, compared to the consensus estimate of $7.07 million.

CORI has been the topic of several analyst reports. Zacks Investment Research lowered shares of Corium International from a “buy” rating to a “hold” rating in a research report on Thursday, April 5th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $14.00 price target on shares of Corium International in a research report on Tuesday, March 27th. ValuEngine raised shares of Corium International from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Finally, BidaskClub lowered shares of Corium International from a “buy” rating to a “hold” rating in a research report on Tuesday, March 13th. Two research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $13.00.

Corium International traded down $0.20, hitting $8.01, on Friday, according to MarketBeat Ratings. 560,725 shares of the stock were exchanged, compared to its average volume of 253,928. The company has a current ratio of 8.11, a quick ratio of 7.95 and a debt-to-equity ratio of 1.89. Corium International has a 52 week low of $7.24 and a 52 week high of $13.93. The firm has a market capitalization of $290.30 million, a P/E ratio of -4.88 and a beta of 1.54.

Hedge funds and other institutional investors have recently bought and sold shares of the business. MetLife Investment Advisors LLC bought a new stake in Corium International during the fourth quarter worth $123,000. DekaBank Deutsche Girozentrale bought a new position in shares of Corium International in the first quarter valued at about $167,000. California Public Employees Retirement System bought a new position in shares of Corium International in the fourth quarter valued at about $310,000. Two Sigma Advisers LP bought a new position in shares of Corium International in the fourth quarter valued at about $317,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Corium International by 126.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 32,998 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 18,416 shares during the period. 94.79% of the stock is currently owned by hedge funds and other institutional investors.

Corium International Company Profile

Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.

Get a free copy of the Zacks research report on Corium International (CORI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply